REVIEW

Recent advances in understanding and managing pediatric inflammatory bowel disease [version 1; peer review: 2 approved]

Bhaskar Gurram , Ashish S. Patel

University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA

V1 First published: 13 Dec 2019, 8(F1000 Faculty Rev):2097
<https://doi.org/10.12688/f1000research.19609.1>

Latest published: 13 Dec 2019, 8(F1000 Faculty Rev):2097
<https://doi.org/10.12688/f1000research.19609.1>

Abstract

The landscape of pediatric inflammatory bowel disease is rapidly evolving. The therapeutic advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists and evaluated in both controlled trials and real-world experience. Though anti-tumor necrosis factor agents have been the primary therapy over the last decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy. By reviewing epidemiology, pathophysiology, and goals of treatment, we hope to frame the discussion of current and novel therapeutics for the pediatric gastroenterologist. As scientific discovery continues to push the envelope in defining our understanding of pediatric inflammatory bowel disease, the current era of therapeutics gives us hope that a cure may be realized soon.

Keywords

pediatric inflammatory bowel disease, Crohn's disease, ulcerative colitis

Open Peer Review

Approval Status

	1	2
version 1
13 Dec 2019		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Jaroslav Kierkus**, The Children's Memorial Health Institute, Warsaw, Poland
2. **Athos Bousvaros**, Boston Children's Hospital, Boston, USA
Naamah Zitomersky, Boston Children's Hospital, Boston, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Ashish S. Patel (Ashish.patel@utsouthwestern.edu)

Author roles: **Gurram B:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Patel AS:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Gurram B and Patel AS. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Gurram B and Patel AS. **Recent advances in understanding and managing pediatric inflammatory bowel disease [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):2097 <https://doi.org/10.12688/f1000research.19609.1>

First published: 13 Dec 2019, 8(F1000 Faculty Rev):2097 <https://doi.org/10.12688/f1000research.19609.1>

Introduction

The landscape of pediatric inflammatory bowel disease (IBD) is rapidly evolving. The therapeutic advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists and evaluated in both controlled trials and real-world experience. Additionally, pediatrics is leading the way in several key areas including the understanding of IBD as a monogenic disease in early onset (less than 10) and very early onset (less than 6) cases and around diet as primary therapy utilizing regimens including the specific carbohydrate diet (SCD) and exclusive enteral nutrition (EEN). Just a short 10 years ago, primary therapy in pediatric IBD centered around steroids and oral immunomodulators. With the advent of the first anti-tumor necrosis factor alpha (TNF- α) inhibitor, we were ushered into the biologic era. Anti-TNF agents were more efficacious drugs with the potential for sustained remission. Pediatric gastroenterologists began discussing the potential for an effective therapy like an anti-TNF to change the natural history of this previously aggressive and progressive disease. Though anti-TNFs were the main drug to occupy this class for almost a decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy.

As we continue to increase our understanding of therapeutics, the natural evolution of thought shifts from merely modulating the body's inflammatory response to actually curing the disease. Most current Venn diagrams of pediatric IBD pathophysiology intersect genetic susceptibility, environmental triggers, host immune response, and the gut microbiome resulting in IBD. A key driver, particularly in pediatrics, is the concept that in young children this may be more of a monogenic than a multifactorial disease, as described above. Work by investigators like Dr. Scott Snapper and consortiums like the International Early Onset Paediatric IBD Cohort Study (NEOPICS) has identified unique monogenic immune defects previously classified under the IBD nomenclature that are actually unique defects that have an IBD-like presentation and represent monogenic defects that mimic IBD. These diseases respond and can be cured by treatments like bone marrow transplantation rather than the traditional immunosuppression used in IBD.

The understanding of pediatric IBD has also been greatly influenced by the development of the Improve Care Now (ICN) network, led by Dr. Richard Colletti. The network began with 12 centers in 2007, named the Trailblazer Consortium, and has evolved to 107 centers worldwide all pushing the envelope of quality care, resulting in standardized evaluation, consistent therapeutic dosing, focus on nutrition and growth, and, in the end, sustained steroid-free remission. The ICN network has developed clinical pathways, which we will highlight in the appropriate areas, in addition to consistently contributing to the pediatric literature on optimal IBD care.

Epidemiology

The incidence and prevalence of Crohn's disease (CD) and ulcerative colitis (UC) varies widely across the globe, and there is a paucity of data from many developing countries. Overall, it

appears that the rates of pediatric IBD are increasing globally in both developed and developing countries; however, accurate estimates are lacking¹. Based on the reports, there appear to be variations within a country based on geographic location. For example, in the USA, the incidence in Texas was lower compared to the incidence in Wisconsin (2.4 versus 9.5 per 100,000 population, respectively)^{2,3}. Population-based health administrative data from Canada showed an incidence of pediatric IBD to be 9.68 per 100,000 population, which means Canada has one of the highest incidences of pediatric IBD in the world⁴. In addition, this study did not find a change in the overall incidence for the duration of study between 1999 and 2010. However, there was an increase in incidence in children between 0 and 5 years of age.

Racial and geographic differences in the incidence have been well described. In British Columbia, South Asians had a three-fold higher incidence of pediatric IBD than non-South Asians, and they had a distinct phenotype with more extensive colonic disease and severe disease compared to the non-South Asian population^{5,6}. Asian and Hispanic children develop UC more often than CD⁷. A higher prevalence with increasing latitudes has been noted for pediatric-onset CD in Scotland⁸ and for UC in Finland⁹. In a population-based study in Europe, the combined incidence rates for CD and UC in all western European centers were twice as high as the rates in the Eastern European centers, implicating a geographic variation in IBD incidence¹⁰.

Advances in the understanding of pediatric IBD pathophysiology

IBD is thought to be of multifactorial origin with complex interaction between genes and environment. Twin studies and family studies have suggested a strong genetic component to IBD pathogenesis and incidence¹¹. Although having a first-degree relative with IBD confers a greater risk (risk of CD to first-degree relatives of CD patients was 10-fold greater and the risk of UC to relatives of UC patients was eightfold greater than the risk of CD or UC to first-degree relatives of healthy controls) than any known environmental factor, the rate at which the incidence has increased worldwide over the past century¹² and more recently in Asia¹³ significantly exceeds that which can be explained by a genetic drift alone. Genome-wide association studies have identified over 200 genetic loci associated with IBD¹⁴. These genes are implicated in immune homeostasis and the regulation of innate functions like response to microbiota, autophagy, endoplasmic reticulum stress response, and mucosal barrier integrity. These loci are also implicated in adaptive immune function¹⁵, yet combined these explain only 15 to 26% of heritability for IBD. Moreover, these genetic variations are population specific, and more than 70% of these genetic loci are shared with other autoimmune diseases like type 2 diabetes and rheumatoid arthritis.

The gut microbiome is thought to play a significant role in the pathogenesis of IBD. Studies have shown alterations in the microbiome in IBD patients compared to healthy controls with decreases in diversity and abundance. However, there are significant inconsistencies regarding the results, potentially from

how the microbiome studies were conducted and interpreted. It remains unclear whether microbiome changes lead to intestinal inflammation or change as a result of it.

The true interaction between genes and the environment is very difficult to discern and likely involves a complex multi-directional interplay mediated by the epigenome, microbiota, and the innate and acquired immune system.

Goals of treatment

IBD, especially CD, is an aggressive and progressive illness that can lead to irreversible bowel damage. With the introduction of biologics, the approach to the management of IBD has changed from controlling symptoms which do not necessarily correlate with inflammation to achieving mucosal healing a more objective measure. Thus, over the past two decades, there has been a shift in the treatment goal from relief of symptoms to inducing mucosal healing while continuing to maintain growth, support nutrition, improve quality of life, and minimize side effects. Preliminary support for this paradigm shift came from the first large trial of infliximab (IFX), ACCENT-I. Patients who achieved mucosal healing were less likely to have CD-related hospitalizations and surgery¹⁶. Furthermore, using mucosal healing as an end point for decision making was found to be more cost-effective than a strategy based on clinical symptoms by decreasing disease-related complications¹⁷.

There are several other markers in the management of IBD. These include CRP, albumin, fecal calprotectin, and antibodies against various antimicrobial antigens¹⁸. Although elevated CRP correlates well with both endoscopic and histologic evidence of inflammation, in patients with isolated small bowel CD and those with UC the correlation with disease activity is poor¹⁹. Similarly, although calprotectin is considered a good marker of intestinal inflammation, especially in UC, it does not correlate well with CD activity, especially small bowel CD¹⁸.

There are several reports discussing the role of serological markers in IBD management. One study involving a large pediatric multicenter cohort demonstrated that disease progression from uncomplicated to internal penetrating or stricturing disease phenotypes and CD-related surgery is accelerated in the presence of antimicrobial immune reactivity that included anti-Cbir1 (flagellin), anti-outer membrane protein C antibody (anti-ompC), anti-*Saccharomyces cerevisiae* antibody (ASCA), and perinuclear anti-neutrophil cytoplasmic antibody (pANCA). Both the number of immune responses and the magnitude of immune response to various microbial antigens were predictive of aggressive disease phenotypes. The group positive for all three antibodies and those patients with the highest magnitude of response (the highest quartile sum group 4) exhibited the most rapid disease progression²⁰. The odds ratio (OR) for the development of internal penetrating disease was 5.0 and 9.5 for children with reactivity to two and three antigens, respectively. Another cross-sectional study involving an adult population demonstrated that patients who were positive for ASCA IgA and IgG were 8.5 times and 5.5 times more likely to undergo early (<3 years) surgery than patients negative for ASCA IgA and IgG²¹.

Several studies have suggested that nucleotide-binding oligomerization domain 2 (*NOD2*) mutations are associated with an increased risk of complicated CD. The *NOD2* gene codes for NOD 2 protein, which is an intracellular pattern recognition receptor primarily involved in recognizing muramyl dipeptide, a molecule present on certain bacteria, and helps in modulating the immune system. In a meta-analysis, Adler *et al.* reported that the presence of a single *NOD2* mutation predicted an 8% increase in the risk for complicated disease (B2 or B3) and a 41% increase with two mutations²². Although the predictive power associated with a single *NOD2* mutation for complicated disease was weak (relative risk: 17%), the presence of two *NOD2* mutations had 98% specificity for predicting complicated disease²². However, *NOD2* mutations were poor predictors for postoperative recurrence of CD²³.

Kugathasan *et al.* derived a risk stratification model for complicated disease behavior based on clinical, serological, gene expression pattern, and microbiota data on 913 treatment-naïve pediatric CD patients²⁴. These patients were prospectively followed for about 36 months and it was found that about 9% (78) of patients had complicated disease course. This risk stratification model had an area under the receiver operator characteristic curve of 0.72, sensitivity of 69%, specificity of 71%, positive predictive value of 24%, and negative predictive value of 94%. Older age at diagnosis, African American race, and ASCA and Cbir1 sero-positivity were associated with disease complications; early anti-TNF- α therapy was associated with a reduction in penetrating disease, and an ileal extracellular matrix gene signature at diagnosis was associated with stricturing disease.

Serological markers (ASCA, pANCA, anti-cbir1, anti-flagellin, etc.) and genetic markers are rarely used in clinical practice, as their applicability is limited by their limited sensitivity and the added cost.

Seigel *et al.* developed and validated a tool (Personalized Risk and Outcome Prediction Tool [PROSPECT]) to predict an individual patient's risk of developing a CD complication based on clinical, serologic, and genetic variables²⁵. The PROSPECT tool generates an individualized risk based on the information provided and groups the patients into low, medium, and high risk for surgery in 3 years and could help physicians and patients on personalized treatment options.

Exclusive enteral nutrition

EEN has been used for several decades in the induction of remission in patients with CD. It is more widely prescribed in Canada and the European nations than in the US. EEN involves supplying 100% of one's caloric needs as a formula, polymeric or hydrolyzed, enterally for 8–12 weeks. The remission rates in most cohort studies range from 60 to 80%^{26–28}, which is equivalent to corticosteroid remission rates. When compared to corticosteroids, which are also used for the induction of remission, EEN is as effective at decreasing symptoms and biochemical markers of inflammation (ESR and CRP) but, unlike steroids, it also leads to decreased endoscopic severity

grossly and histologically^{28,29}. When compared to corticosteroids, EEN is also associated with improved linear growth, bone mineralization, and lean body mass acquisition as opposed to fat mass acquisition with corticosteroids; additionally, it is not immunosuppressive^{30,31}. Therefore, EEN can be particularly helpful in patients with significant growth failure or malnutrition.

European and North American guidelines recommend EEN as the first-line agent in active luminal CD diagnosed under 17 years of age^{32,33}. Although early data indicated that EEN was more likely effective in patients with small bowel involvement³⁴, subsequent data have shown effectiveness regardless of the site of involvement²⁷. However, efficacy has not been demonstrated in perianal, fistulizing, or stricturing CD.

In a recent meta-analysis, Swaminathan *et al.* demonstrated that EEN is equally efficacious in inducing remission in newly diagnosed (OR = 1.61 [95% CI 0.87, 2.98]) and relapsed (OR = 0.76 [95% CI 0.29–1.98]) patients³⁵. In this study, the likelihood of achieving mucosal healing was higher with EEN compared to steroids. Biomarker normalization did not differ.

The exact mechanism of action has remained uncertain, but various mechanisms have been proposed, including decreased antigen exposure, alteration of the resident microbiome³⁶, restoration of epithelial barrier integrity, and decreased immune system activation³⁷.

Specific carbohydrate diet and other diet-based therapies

The SCD was first developed in the 1920's by Dr. Sydney Haas as a therapy for celiac disease and later popularized by a mother of one of Dr. Haas' patients, Elaine Gottschall, a biochemist who wrote the book *Breaking the Vicious Cycle: Intestinal Health Through Diet*. The diet is a nutritionally balanced one that removes grains, dairy, processed foods, and sugars, except for honey. The theory is that these items pass undigested or poorly digested into the distal intestine, allowing the overgrowth of harmful bacteria. This has been re-energized recently by the work of Dr. David Suskind at Seattle Children's who has published several small case series showing the efficacy of the SCD in treating pediatric IBD^{38–41}. The diet is being evaluated nationally in a trial called PRODUCE led by the ICN network centers.

The CD exclusion diet (CDED) is an exclusion diet supplemented with partial enteral nutrition. This involves eliminating certain foods that are deemed to induce dysbiosis, specifically gluten, dairy products, gluten-free baked goods and breads, animal fat, processed meats, products containing emulsifiers, canned goods, and all packaged products with an expiration date. CDED has been studied and found to be beneficial in both children and adults with IBD. In a recent randomized study that included 78 pediatric patients with mild-to-moderate CD, CDED was found to be better tolerated and had higher rates of remission compared to EEN⁴². Other less-well-studied diets in IBD include ordinary food-based diets that replicate EEN (CD-TREAT)⁴³, the food influence on Intestinal Microbiota diet⁴⁴, the anti-inflammatory diet⁴⁵, and low-fermentable oligosaccharide,

disaccharide, monosaccharide, and polyols (low FODMAP) diet⁴⁶.

5-aminosalicylic acid (5ASA) compounds

5-ASA compounds are one of the earliest compounds introduced for the management of IBD. Sulfasalazine was the only 5-ASA formulation shown to have modest benefit compared to placebo in mild-to-moderate CD restricted to the colon⁴⁷. They are not found to be of any benefit in small bowel CD or in moderate-to-severe CD and should not be used^{48–50} in these patients. ECCO and ESPGHAN guidelines recommend 5-ASA compounds as first-line agents for the induction and maintenance of mild-to-moderate UC⁵¹. Combination of oral and rectal 5-ASA therapy is considered superior to 5-ASA monotherapy⁵². The ICN Model IBD Care document recommends oral dosing of 60 to 100 mg/kg/day in active disease and 30 to 100 mg/kg/day in maintenance phase. In a randomized controlled study of mesalamine, there was no difference in the efficacy of once versus twice daily dosing for mild-to-moderate pediatric UC⁵³; thus, once-daily dosing is encouraged to improve patient compliance. The overall efficacy as measured by steroid-free remission at 1 year with mesalamine ranges from 32 to 45%⁵¹. Sulfasalazine was found to be superior to other 5-ASA medications but also had increased side effects^{54,55}. It is estimated that up to 20 to 25% of patients discontinue sulfasalazine because of side effects. The most common side effects encountered with sulfasalazine include nausea, headache, fever, and rash. Curcumin (an active component of turmeric) 3 g/day with mesalamine was found to be more effective than mesalamine alone in achieving clinical and endoscopic remission in patients with mild-to-moderate UC without an increase in adverse effects⁵⁶.

Thiopurines

Azathioprine (AZA) and 6-mercaptopurine (6-MP) have traditionally been the first-line immunomodulators used for the maintenance of remission in CD and UC. However, data concerning long-term risks with thiopurines including skin cancer, lymphoma, and hepatosplenic T-cell lymphoma, particularly in young males receiving thiopurines alone or in combination with anti-TNF- α antibodies, have led pediatric gastroenterologists to favor methotrexate (MTX) in children with CD. Results from the multicenter pediatric IBD network (PIBDNet) showed that 69% of patients (45 of 65 patients) achieved remission within 180 days of thiopurine initiation. However, only 47% and 23% remained in sustained steroid-free remission at 6 and 12 months, respectively. There was significant variation in the dose of thiopurine used, and there was variation in serum 6-TG levels⁵⁷.

AZA is a prodrug and is converted non-enzymatically to 6-MP. Although AZA and 6-MP could be used interchangeably, the dosing is different. The recommended dose for AZA is 1.5 to 2.5 mg/kg per day orally (maximum dose 200 mg per day), and 6-MP is generally given at doses of between 1 and 1.5 mg/kg per day orally (maximum 150 mg per day). To determine a safe starting dose, thiopurine methyltransferase genotype (TPMT genotype) or phenotype (TPMT activity) testing is recommended

prior to beginning treatment with 6-MP or AZA. TPMT is an enzyme that is essential in the metabolism of thiopurines. Approximately 90% of patients are homozygous for the allele TPMT 1 (TPMT 1/1 genotype) and have normal or rapid metabolism of thiopurines. In contrast, 10% of patients have reduced TPMT activity (TPMT 1/3a genotype) and metabolize thiopurines more slowly. These patients typically respond to much lower doses of the medication (0.5 mg/kg/day of 6-MP). Approximately 1 in 300 patients has absent TPMT activity (TPMT 3a/3a genotype), does not metabolize the medication, and can develop agranulocytosis^{58,59}.

However, in a systematic review, thiopurine metabolite testing did not safely predict clinical outcome but may facilitate toxicity surveillance and treatment optimization in poor responders⁶⁰. Current evidence favors the combination of thiopurine metabolites, WBC and aminotransferase monitoring for prompt identification of hematologic and hepatic toxicity, safe dose adjustment, and treatment modification in cases of suboptimal clinical outcome or non-compliance^{60–62}. All patients should have regular clinic follow-up with documented lymph node exam and abdominal palpation for hepatic or splenic enlargement.

Although thiopurines may be effective in prolonging response and remission⁶³, adverse side effects may reduce their utilization. In one series that looked at 95 children and adolescents with IBD who received AZA or 6-MP, 54% had no adverse effect, 28% experienced side effects necessitating dose reduction (elevated liver transaminases, leukopenia, and lymphopenia), and 18% required drug discontinuation because of pancreatitis, recurrent fever, nausea and/or vomiting, and recurrent infections such as sinusitis⁶⁴.

A newer formulation of 6-MP is being developed that is locally active and is a delayed-release formulation with minimal systemic absorption. In a phase II study, Israeli *et al.* reported that in CD when compared to systemically delivered 6-MP (Purinethol), delayed-release 6-MP (DR-6MP) showed similar efficacy, a greater proportion of remission with low systemic bioavailability, and a low incidence of side effects⁶⁵.

Owing to the published risk of hemophagocytic lymphohistiocytosis (HLH) with primary EBV while on thiopurines, there is a growing practice of screening all newly diagnosed children for EBV status and, if naïve, avoiding all thiopurine use.

Methotrexate

MTX is an anti-folate agent that is used for induction and maintenance of remission in CD^{66,67}. It is not useful in the management of UC^{68–70}. Most of the evidence for efficacy in pediatric patients comes from several retrospective pediatric series, a recent systematic review⁷¹, and extrapolated information from one randomized placebo-controlled trial in adults with CD⁷². The pooled achieved clinical remission rate for pediatric CD

patients on monotherapy within 3–6 months was 57.7% (95% CI 48.2–66.6%) ($P = 0.22$; $I^2 = 29.8\%$). The clinical remission was 37.1% (95% CI 29.5–45.5%) ($P = 0.20$; $I^2 = 37.4\%$) for maintenance therapy at 12 months⁷¹. In general, MTX given orally has significant variability in bioavailability among individuals; subcutaneous injection is the preferred formulation⁷³. The superiority of subcutaneous MTX compared to oral MTX is well demonstrated in rheumatology literature⁷³.

MTX has dose-limiting side effects including hepatotoxicity and bone marrow suppression. In one systematic review that included 12 high-quality studies evaluating hepatotoxicity (defined as elevated liver transaminases) when used in a pediatric IBD population, Valentino *et al.* described hepatotoxicity in 1 in 10 patients, 1 in 15 patients needed dose reduction, and 1 in 22 patients needed discontinuation of MTX. Based on these findings, the authors recommended monitoring liver biochemistries at baseline, every 2 weeks for the first month, and then every 2–3 months⁷⁴. Although there is insufficient literature looking at the utility of folate supplementation with MTX in the IBD population, it is known to be beneficial in patients with rheumatoid arthritis. In rheumatoid arthritis, folate supplementation (1 mg/day) with MTX is known to reduce the risk of side effects including liver transaminase elevation and gastrointestinal side effects like nausea and vomiting^{75,76}. Folate supplementation also promoted compliance and reduced patient withdrawal compared to placebo⁷⁶.

Anti-TNFs

IFX, a chimeric monoclonal antibody against TNF- α , is the most commonly used biologic in the treatment of children with CD and UC. Standard IFX dosing in children is 5 mg/kg at 0, 2, and 6 weeks during induction followed by maintenance doses of 5 mg/kg every 8 weeks.

The REACH trial⁷⁷ is a landmark study showing the efficacy of IFX in children for induction and maintenance of remission in moderate-to-severe CD. In this study of 112 children with CD, approximately 60% of patients had clinical response or remission at 1 year. Subsequent studies have shown that up to 50% of patients would need dose modification by 54 weeks to retain or regain efficacy^{78–80}. Following maintenance therapy initiation, the likelihood of continuing maintenance IFX at 1, 2, and 3 years was 93%, 78%, and 67%, respectively⁸⁰.

In moderate-to-severe active pediatric UC that failed conventional therapy (5-ASAs, corticosteroids, or immunomodulators), IFX was found to be safe and effective, inducing a response at week 8 in 73.3%⁸¹. However, the overall remission rate at week 54 for all enrolled patients was 28.6%⁸¹.

Current evidence indicates that the treatment failure may result in part from low IFX serum levels. IFX trough levels of <3 mg/ml are associated with worse clinical outcomes, and dose

optimization based on trough levels has proven beneficial in some studies^{78,82,83}. Factors contributing to the observed pharmacokinetic differences include BMI and sex, inflammatory burden (extent and severity of disease), serum albumin, and presence or absence of a concomitant immunomodulator and of anti-drug antibodies (neutralizing antibodies)⁸⁴. Among these factors, weight and serum albumin levels have been found to have the largest influence⁸⁴. In one pediatric study looking at the correlation of serum IFX levels at week 14 as predictors of remission at week 54, the authors found that trough levels of at least 3 mg/ml were associated with a positive predictive value of only 76% for persistent clinical remission at week 54⁷⁸. Increasing the trough threshold to at least 7 mg/ml improved the positive predictive value of persistent remission at week 54 to 100%⁷⁸.

Using the data from 112 patients with CD in the REACH trial, Frymoyer *et al.* constructed a Monte Carlo simulation analysis of hypothetical children with CD to address dose optimization of IFX based on weight and albumin levels. They found that standard IFX maintenance dosing of 5 mg/kg every 8 weeks is predicted to frequently result in trough concentrations of <3 mg/ml in children with CD with an albumin of 4 g/dl or less⁸⁵. They estimated that only 21% or 41% of children would achieve trough concentrations of >3 mg/ml if albumin levels were 3 g/dl or 4 g/dl, respectively, and thus a substantial proportion of patients would need an increase in dose and frequency to maintain adequate drug exposure at week 14⁸⁵.

Thus, early IFX trough levels could help in guiding dose optimization and likely improve clinical outcomes. Although therapeutic drug monitoring (TDM), defined as the evaluation of levels of drug and anti-drug antibodies, has proven to be effective in optimizing anti-TNF therapy in maintenance phase of IBD, the studies are limited to monitoring levels in induction phase. However, logically thinking, it is likely that there is a beneficial effect of monitoring levels during induction phase and optimizing them rather than waiting until the maintenance phase. Based on preliminary data in adults with UC, week 2 and week 6 trough levels of 30 to 36 and 24 to 30 mg/ml at week 2 and 6, respectively, were associated with early mucosal healing⁸⁶. In children with moderate-to-severe UC, week 8 levels of serum IFX concentrations (≥ 41.1 $\mu\text{g/ml}$) were associated with greater proportions of patients achieving efficacy endpoints (clinical response: 92.9%; mucosal healing: 92.9%; and clinical remission: 64.3%) versus those with lower serum concentrations (<18.1 $\mu\text{g/ml}$; 53.9%, 53.9%, and 30.8%, respectively)⁸⁷. A retrospective study from a tertiary care center demonstrated that interval shortening rather than dose escalation results in higher IFX levels, and the authors recommended a dose of every 6 weeks for optimizing levels⁸⁸.

Based on the above data, we recommend checking IFX trough levels before the fourth dose (week 14 dosing) in CD to guide subsequent intervals between dosing and achieve target levels

of >5 mg/ml. For IFX in severe UC, our practice has been to start with 10 mg/kg, in particular in patients with documented hypoalbuminemia. For UC, we recommend checking levels before the third (week 6 dosing) induction dose with levels of >20 mg/ml and adjusting the subsequent doses accordingly.

Adalimumab, a human IgG monoclonal antibody against TNF- α , was approved for use in children with CD in 2012. The standard recommended dosing in children weighing >40 kg is 160 mg and 80 mg for induction 2 weeks apart and 40 mg every 2 weeks for maintenance. For children weighing <40 kg, induction dosing is 80 mg and 40 mg 2 weeks apart and 20 mg every 2 weeks for maintenance. In the pivotal study IMAGINE 1, using adalimumab in moderate-to-severe CD, 33.3% of patients remained in remission at week 54. Patients who were naïve to IFX had higher remission rates (45% versus 19%)⁸⁹. About 50% of patients in the IMAGINE 1 trial needed dose escalation to weekly dosing from every other week dosing based on clinical symptoms; this frequent dosing was well tolerated⁹⁰. The IMAGINE 2 study assessed the long-term efficacy through week 240 of adalimumab⁹¹. At week 240, about 41% and 48% of those enrolled achieved remission and response as assessed by PCDAI<10 and PCDAI decrease by >15 points from baseline, respectively⁹¹. In a systematic review that included 14 studies (one randomized controlled trial and 13 case series) and 664 patients, the pooled remission rates were 44% (n = 169/383) at 12 months. Of the total patients, 6% (n = 13/207) were classified as primary non-responders and 12% (n = 69/599) had severe adverse events reported, including two deaths and one medulloblastoma⁹².

Based on a network meta-analysis of five randomized controlled trials in moderate-to-severe adult UC, adalimumab was comparable in efficacy to IFX at 52 weeks of maintenance treatment⁹³. Based on the retrospective studies, adalimumab in pediatric UC showed similar results to those of adults with UC⁹⁴. While on adalimumab, reactive TDM is recommended in adults, with a recommended minimum drug concentration at week 4 of >7 mg/ml to achieve mucosal healing and levels of >5 mg/ml during maintenance phase^{95,96}.

Golimumab, another human IgG monoclonal antibody against TNF- α , is approved for use in adults with UC. In an open-label pharmacokinetic study of 35 children with moderate-to-severe UC, golimumab showed a week 6 clinical response in 60%, with mucosal healing achieved in 23%, and clinical remission in 57% at week 14^{96,97}. The recommended dosing in children with UC for induction is 200 mg at week 0 and 100 mg at week 2 if body weight is >45 kg and 120 mg/m² at week 0 and 60 mg/m² at week 2 if body weight is <45 kg. Maintenance dosing is 100 mg every 4 weeks for >45 kg body weight and 60 mg/m² every 4 weeks if body weight is <45 kg^{96,97}. In adults, the expected minimum concentration at week 6 for golimumab should be >2.5 mg/ml, and maintenance trough levels should be >1 mg/ml⁹⁵.

Safety issues of TNF- α medications include acute infusion reactions (within 4 hours of IFX infusion), delayed hypersensitivity reactions (beyond 4 hours and up to 14 days), and serious and opportunistic infections. In one retrospective study that included a total TNF- α exposure of 390.5 patient-years (PYs), the overall incidence rate of serious adverse events (SAEs) for IFX was 22.49/100 PYs⁹⁸. The most common SAEs were anaphylactoid reactions (n = 18) followed by infectious events (n = 9) and TNF- α antagonist-induced lupus-like syndrome (n = 3). The overall incidence rate of SAEs for adalimumab was 4.71/100 PYs (two infectious SAEs). No malignancies or deaths were observed in this cohort. When used as monotherapy TNF- α medications are not associated with increased risk of malignancy or HLH in the pediatric population⁹⁹. However, in the adult population, there is increased risk of malignancies even with monotherapy, with the highest risk associated with combination therapy with thiopurines¹⁰⁰. Psoriasis has been well documented as an adverse class effect of TNF- α , but it is usually mild and controllable in most patients with topical therapy¹⁰¹.

There is no clear evidence that pre-medication with IFX prevents the development of acute infusion reaction¹⁰², and we do not routinely use or recommend the use of pre-medications prior to IFX infusion. Recommended infection screening before starting TNF- α medications includes screening for tuberculosis (PPD, quantiferon TB, or chest X-ray), hepatitis B (Hep B surface antigen and antibody), and varicella immunization status (confirmed vaccination, exposure, or checking for varicella IgG)⁵¹.

Combination therapy

The use of an immunomodulator drug, either thiopurine (AZA or 6-MP) or MTX, with TNF- α antibody is termed combination therapy. Demonstrated benefits of combination therapy include a reduction in the formation of antibodies to TNF- α and increased durability of biologic response¹⁰³. However, the benefits on clinical remission and mucosal healing are unclear. Some of the risks to consider in using combination therapy are increased risk of infections and increased risk of malignancy.

The SONIC trial comparing the efficacy of AZA, IFX, and AZA+IFX that included 508 patients with CD naïve to AZA and IFX showed higher steroid-free remission and mucosal healing with combination of AZA and IFX¹⁰⁴. Combination therapy with AZA appears to improve efficacy by increasing the pharmacokinetic features of IFX¹⁰⁵. Based on these data, the American Gastroenterological Association (AGA) recommended using combination therapy for induction of remission in adults with CD¹⁰⁶.

Data on combination therapy in pediatric CD comes from one randomized controlled trial and several retrospective studies and the results are inconclusive, with some studies showing no benefit of combination therapy^{107–111} and others showing benefit with regard to remission and durability of response to combination

therapy^{112–116}. One therapeutic option is to use low-dose immunomodulators in combination with TNF- α antibodies^{113,117}.

Two important safety concerns with the use of combination therapy are increased risk of infections and malignancy. Two of the important risk factors for increased risk of infection in IBD patients were identified to be moderate-to-severe disease and concomitant steroid use. A clinical report on combination therapy by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) concluded that based on the adult literature, the use of combination therapy may have a net effect of reducing infectious risk in select patients by improving disease remission rates and minimizing steroid use¹¹⁸.

With regard to malignancy risk, especially with lymphoma, the risk is primarily attributed to thiopurines and there may be a slight increased risk when anti-TNFs are used in combination^{99,119}. One exception is hepatosplenic T cell lymphoma (HSTCL). An increased incidence of HSTCL has been reported in young male patients treated with either thiopurines as monotherapy or in combination with a TNF- α ^{120,121}.

Taking the above benefits and risks into consideration, there certainly is a group of patients who benefit from using combination therapy to induce remission and prevent long-term risks associated with CD while at the same time minimizing the side effects of combination therapy. At our center, we typically use combination therapy in patients with moderate-to-severe CD, especially with stricturing or fistulizing disease and severe perianal disease. We prefer to use MTX over thiopurines in males and those with no evidence of EBV infection in the past. We also use lower doses of immunomodulators when used in combination with TNF- α drugs.

Anti-adhesion agents

Anti-adhesion molecules act by blocking the trafficking of T-lymphocytes from the lymphoid organs and bloodstream to the site of gut inflammation. There are two medications in this group. Natalizumab was the first anti-adhesion agent approved for the management of moderate-to-severe CD. Natalizumab is a monoclonal antibody against the α 4 integrin on lymphocytes. Specifically, it blocks the α 4 β 7 and α 4 β 1 integrins on the T cells from binding mucosal addressin cell adhesion molecule-1 (MADCAM-1) and vascular cell adhesion molecule-1 (VCAM-1), respectively¹²². Natalizumab, in comparison to placebo, has been reported to be more effective in the induction and maintenance of remission in patients with CD¹²³. The evidence in pediatrics is limited to two case series^{124,125}. Hyams *et al.* included 31 adolescents with severe CD and reported a response rate of 55% and remission of 29% at 10 weeks¹²⁴.

Natalizumab's use has been drastically limited by its association with progressive multifocal leukoencephalopathy (PML), a life-threatening CNS infection caused by the reactivation

of John Cunningham virus (JCV). This side effect is thought to be directly related to the blockade of lymphocyte migration to the CNS by natalizumab. The risk factors implicated in PML include the presence of positive anti-JCV antibodies, prior immunosuppressant therapy, and prolonged duration of natalizumab therapy (>2 years). Although natalizumab was withdrawn from the US market in 2005, it was reintroduced in 2008 under restricted usage in patients with none of the risk factors mentioned above¹²³.

The second anti-adhesion biologic is vedolizumab. Vedolizumab is a monoclonal antibody against $\alpha 4\beta 7$ integrin on lymphocytes, blocking their binding to MADCAM-1 and thus migration of the lymphocytes into the gastrointestinal tract mucosa. As opposed to natalizumab, vedolizumab is gut specific and does not lead to systemic immunosuppression and thus the side effects were found to be very similar to those seen with placebo¹²⁶. Vedolizumab has been found to be superior to placebo for induction of remission at week 6 for adult-onset CD and UC subjects with moderately to severely active disease^{126–130}. In a single-center prospective observational study, Conrad *et al.*¹³¹ followed 21 pediatric patients (13 to 21 years) with severe TNF- α -refractory IBD (16 CD, three UC, and two IBD-U). They reported a response rate in 57.9% of patients at 22 weeks with steroid-free remission of 20% at 22 weeks. Hamel *et al.*¹³², in a retrospective cohort of 12 TNF- α and corticosteroid-refractory IBD patients (10 UC and two CD), reported that when vedolizumab used in combination with tacrolimus 9 of 12 (75%) patients avoided colectomy or IBD-related surgery at 24 weeks and 8 out of 12 (68%) continued on vedolizumab maintenance with no adverse events up to 80 weeks. A retrospective multicenter study from the pediatric IBD Porto group of ESPGHAN included 64 children with IBD (41 UC/IBD-U and 23 CD) refractory to TNF- α medications and reported a week 14 corticosteroid-free remission of 37% in UC and 14% in CD¹³³. Similarly, in a retrospective multicenter study from the US involving 52 IBD patients (58% CD and 42% UC), the authors reported a 14 week remission rate of 76% in UC and 42% in CD¹³⁴. The dose of vedolizumab used in children is 6 mg/kg with a maximum dose of 300 mg, with induction given at 0, 2, and 6 weeks followed by maintenance every 8 weeks^{134,135}. The recently released VARSITY study (Sands *et al.*, DDW 2019) showed vedolizumab to have superior efficacy versus adalimumab for moderate-to-severe UC. This was a phase IIIB randomized double-blind study of 769 adults with moderately to severely active UC who had failed other therapies. Clinical remission at week 52 was the primary endpoint and was 31% with vedolizumab compared to 22% with adalimumab, and patients treated with vedolizumab had higher mucosal healing rates. Adverse events were similar in the two groups. This is an important study because it is the first comparative effectiveness study in IBD comparing two biologic therapies head to head. As opposed to natalizumab, vedolizumab has an excellent safety profile. The most frequently reported adverse events are minor and include headaches, fever, arthralgias, and nausea^{126,127,129,136}. Infusion reactions are low at 3.5 per 1,000 infusions^{136,137}.

Etrolizumab is a humanized monoclonal antibody against the $\beta 7$ subunit of $\alpha 4\beta 7$ and $\alpha E\beta 7$ which prevents their interaction with MADCAM-1 and E-cadherin, respectively, and thus disrupts leukocyte migration into intestinal tissue¹²³. Etrolizumab has been shown to be well tolerated and effective in a phase II clinical trial of patients with moderate-to-severe UC¹³⁸; phase III clinical trials are underway. There are no pediatric studies of Etrolizumab to date.

Other medications in this group include AJM300, an orally active, small molecule with a mechanism of action like natalizumab, and PF-00547659, a monoclonal antibody administered subcutaneously against intestinal epithelial adhesion molecule MADCAM-1¹²³.

Interleukin inhibitors

Interleukin-12 (IL-12) and interleukin-23 (IL-23) are pro-inflammatory cytokines that induce the differentiation of naïve CD4⁺ T cells into T-helper 1 and T-helper 17 cells, respectively, and are important in the pathogenesis of IBD. Ustekinumab is a human monoclonal antibody against the p40 subunit that is common to both IL-12 and IL-23, consequently preventing the interaction of these cytokines with their receptors on naïve T cells and preventing further downstream signaling and the pro-inflammatory cascade. It was approved for the treatment of moderate-to-severe CD in adults in 2016.

The adult UNITI-1 and UNITI-2 studies demonstrated clinical response in adults with TNF- α -naïve and TNF- α -exposed moderate-to-severe CD patients. Responders from UNITI-1 and UNITI-2 were enrolled in a subcutaneous ustekinumab maintenance trial (IM-UNITI), which showed a clinical remission at week 44 of 53.1% in the group that received 90 mg every 8 weeks compared to 48.8% in those receiving ustekinumab every 12 weeks and 35.9% in those receiving placebo¹³⁹. The rates of adverse events were not statistically different between the treatment and placebo arm in all of these trials. Also, ustekinumab is observed to lead to significant reductions in endoscopic disease activity at week 8 of induction therapy¹⁴⁰.

There is an evolving body of literature for the use of ustekinumab in pediatric patients. This consists of case reports, one case series, and a recently published real-world experience on ustekinumab in pediatric patients. In the case series, the suggested dosing is 6 mg/kg IV infusion for induction followed by 45 mg every 8 weeks for maintenance in children weighing <40 kg and 90 mg every 8 weeks for children weighing >40 kg. In the real-world experience, 52 patients receiving ustekinumab were evaluated and included baseline characteristics and predictors of response. The study concluded that ustekinumab monotherapy is possible and preferable in children. A caveat that we have also noted was the need for dose amplification, 57% in this real-world experience^{141–143}. Based on our personal unpublished experience, 8 out of 10 patients with anti-TNF-refractory disease responded to ustekinumab but

needed an augmented dosing schedule of every 4 to 6 weeks during maintenance to maintain a recommended trough level of >4.5 mg/ml.

The second agent in this group is risankizumab, a humanized IgG1 monoclonal antibody that selectively binds with high affinity to the IL-23 p19 subunit and is currently being studied for use in patients with IBD. By specifically targeting the IL-23-mediated inflammatory pathway and thus the T-helper 17 cells without disrupting the IL-12-dependent T-cell pathway, which is thought to be important for infection and cancer immunity, risankizumab theoretically may confer fewer side effects in comparison with ustekinumab¹²³.

JAK/STAT inhibitors

Janus kinases (JAKs) are intracellular signaling molecules that, when activated by cytokines, lead to phosphorylation and dimerization of Signal Transducer and Activator of Transcription proteins (STATs), which migrate into the nucleus and induce further gene transcription that modulates inflammation that is characteristic of IBD¹⁴⁴. The JAK/STAT pathway regulates intracellular signaling involving common gamma chain-containing cytokine receptors for interleukins 2, 4, 7, 9, 15, and 21¹⁴⁵. These cytokines and their downstream JAK/STAT signaling pathways are integral to lymphocyte activation, function, and proliferation. Inhibition of the JAK/STAT signaling pathway is a major area of interest in the development of novel IBD medications¹⁴⁶.

Tofacitinib is an oral, small-molecule inhibitor of JAK1, JAK3, and, to a lesser extent, JAK2. In adults with UC, the rate of remission at 8 weeks was significantly higher in the 10 mg tofacitinib group than in the placebo group in the OCTAVE Induction 1 trial (18.5% versus 8.2%) and in the OCTAVE Induction 2 trial (16.6% versus 3.6%). In the OCTAVE Sustain trial, remission at 52 weeks occurred in 34.3% of patients in the 5 mg tofacitinib group and 40.6% in the 10 mg tofacitinib group compared to 11.1% in the placebo group ($P < 0.001$ for both comparisons with placebo). Side effects, especially rates of serious infection, were higher with tofacitinib than with placebo. However, in the OCTAVE Sustain trial, the rate of serious infection was similar across the three treatment groups, but the rates of overall infection and herpes zoster infection were higher with tofacitinib than with placebo¹⁴⁷. Other side effects noticed include dyslipidemia (high HDL and LDL cholesterol) and increased risk of cardiovascular events and non-melanoma skin cancers¹⁴⁵. In a post hoc analysis of data from the OCTAVE trials, Hanauer *et al.*¹⁴⁸ reported significant improvements in stool frequency and rectal bleeding in UC patients within the first 3 days of induction therapy with tofacitinib compared with placebo. There are no data on the use of tofacitinib in pediatric patients, and it had poor efficacy in adults with CD¹²³.

Filgotinib is a second agent in this group and is a highly selective JAK-1 inhibitor. In phase II clinical trials, filgotinib has been shown to be effective in CD and may be particularly useful in those with previous anti-TNF exposure¹⁴⁹ (Table 1).

Table 1. Medication, dosing, therapeutic drug monitoring, and references.

Medication	Recommended dose for induction	Recommended dose for maintenance	Recommended trough levels for biological remission (µg/ml)	Recommended trough levels for mucosal healing (µg/ml)	Reference
Infliximab	5 mg/kg on week 0, 2, and 6	5 mg/kg every 8 weeks	3–7	>5	78,95
Adalimumab	<40 kg: 80 mg and 40 mg at week 0 and 2 >40 kg: 160 mg and 80 mg at week 0 and 2	<40 kg: 20 mg every 2 weeks >40 kg: 40 mg every 2 weeks	>5.9	>7.5	95,96
Golimumab	<45 kg: 120 mg/m ² on week 0 and 60 mg/m ² on week 2 >45 kg: 200 mg on week 0 and 100 mg on week 2	<45 kg: 60 mg/m ² every 4 weeks >45 kg: 100 mg every 4 weeks	>1.4	NA	95
Vedolizumab	6 mg/kg on week 0, 2, and 6 (max 300)	6 mg/kg every 8 weeks (max 300)	>13.6	NA	95
Ustekinumab	<40 kg: 6 mg/kg 40 to <55 kg: 260 mg 55 to <85 kg: 390 mg >85 kg: 520 mg	<40 kg: 45 mg every 8 weeks >40 kg: 90 mg every 8 weeks	>0.8	>4.5	95

Conclusion

Therapeutic discovery continues to teach us the many intricate and complex pathways of the human inflammatory response in IBD. We must be vigilant to the short-term and long-term effects of all of these medications, even with the new generation of gut-specific therapies. The identification of lymphoma associated with the TNF- α agents was recognized in post marketing

surveillance. However, we must always frame the risk of these medications to our patients in the broader context of the natural history of this aggressive and progressive disease. As scientific discovery continues to push the envelope in defining our understanding of pediatric IBD, the current era of therapeutics gives us hope that a cure may be realized in the not-so-distant future.

References

- Benchimol EI, Fortinsky KJ, Gozdya P, *et al.*: **Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends.** *Inflamm Bowel Dis.* 2011; **17**(1): 423–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, *et al.*: **Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study.** *Inflamm Bowel Dis.* 2013; **19**(6): 1218–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Malaty HM, Fan X, Opekun AR, *et al.*: **Rising incidence of inflammatory bowel disease among children: a 12-year study.** *J Pediatr Gastroenterol Nutr.* 2010; **50**(1): 27–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Benchimol EI, Bernstein CN, Bitton A, *et al.*: **Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases.** *Am J Gastroenterol.* 2017; **112**(7): 1120–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Carroll MW, Hamilton Z, Gill H, *et al.*: **Pediatric Inflammatory Bowel Disease Among South Asians Living in British Columbia, Canada: A Distinct Clinical Phenotype.** *Inflamm Bowel Dis.* 2016; **22**(2): 387–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pinsk V, Lemberg DA, Grewal K, *et al.*: **Inflammatory bowel disease in the South Asian pediatric population of British Columbia.** *Am J Gastroenterol.* 2007; **102**(5): 1077–83.
[PubMed Abstract](#)
- Abramson O, Durant M, Mow W, *et al.*: **Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006.** *J Pediatr.* 2010; **157**(2): 233–239.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Armitage EL, Aldhous MC, Anderson N, *et al.*: **Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence.** *Gastroenterology.* 2004; **127**(4): 1051–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jussila A, Virta LJ, Salomaa V, *et al.*: **High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference.** *J Crohns Colitis.* 2013; **7**(7): e256–e262.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Burisch J, Pedersen N, Čuković-Čavka S, *et al.*: **East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.** *Gut.* 2014; **63**(4): 588–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gordon H, Trier Møller F, Andersen V, *et al.*: **Heritability in inflammatory bowel disease: from the first twin study to genome-wide association studies.** *Inflamm Bowel Dis.* 2015; **21**(6): 1428–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Molodecky NA, Soon IS, Rabi DM, *et al.*: **Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.** *Gastroenterology.* 2012; **142**(1): 46–54.e42. quiz e30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Kamm MA: **Rapid changes in epidemiology of inflammatory bowel disease.** *Lancet.* 2018; **390**(10114): 2741–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Liu JZ, van Sommeren S, Huang H, *et al.*: **Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.** *Nat Genet.* 2015; **47**(9): 979–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Jostins L, Ripke S, Weersma RK, *et al.*: **Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.** *Nature.* 2012; **491**(7422): 119–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Rutgeerts P, Feagan BG, Lichtenstein GR, *et al.*: **Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.** *Gastroenterology.* 2004; **126**(2): 402–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Baert F, Moortgat L, van Assche G, *et al.*: **Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.** *Gastroenterology.* 2010; **138**(4): 463–8. quiz e10-1.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
- Chang S, Malter L, Hudesman D: **Disease monitoring in inflammatory bowel disease.** *World J Gastroenterol.* 2015; **21**(40): 11246–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Vermeire S, Van Assche G, Rutgeerts P: **Laboratory markers in IBD: useful, magic, or unnecessary toys?** *Gut.* 2006; **55**(3): 426–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Dubinsky MC, Kugathasan S, Mei L, *et al.*: **Increased immune reactivity predicts aggressive complicating Crohn's disease in children.** *Clin Gastroenterol Hepatol.* 2008; **6**(10): 1105–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Dubinsky M: **Can serologic markers help determine prognosis and guide therapy?** *Dig Dis.* 2010; **28**(3): 424–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Adler J, Rangwala SC, Dwamena BA, *et al.*: **The prognostic power of the NOD2 genotype for complicated Crohn's disease: A meta-analysis.** *Am J Gastroenterol.* 2011; **106**(4): 699–712.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Solon JG, Burke JP, Walsh SR, *et al.*: **The effect of NOD2 polymorphism on postsurgical recurrence in Crohn's disease: A systematic review and meta-analysis of available literature.** *Inflamm Bowel Dis.* 2013; **19**(5): 1099–105.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kugathasan S, Denson LA, Walters TD, *et al.*: **Prediction of complicated disease course for children newly diagnosed with Crohn's disease: A multicentre inception cohort study.** *Lancet.* 2017; **389**(10080): 1710–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Siegel CA, Horton H, Siegel LS, *et al.*: **A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables.** *Aliment Pharmacol Ther.* 2016; **43**(2): 262–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rubio A, Pigneur B, Garnier-Lengliné H, *et al.*: **The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding.** *Aliment Pharmacol Ther.* 2011; **33**(12): 1332–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Buchanan E, Gaunt WW, Cardigan T, *et al.*: **The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission.** *Aliment Pharmacol Ther.* 2009; **30**(5): 501–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Borrelli O, Cordischi L, Cirulli M, *et al.*: **Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: A randomized controlled open-label trial.** *Clin Gastroenterol Hepatol.* 2006; **4**(6): 744–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fell JM, Paintin M, Arnaud-Battandier F, *et al.*: **Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease.** *Aliment Pharmacol Ther.* 2000; **14**(3): 281–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Whitten KE, Leach ST, Bohane TD, *et al.*: **Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease.** *J Gastroenterol.* 2010; **45**(4): 399–405.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gerasimidis K, Talwar D, Duncan A, *et al.*: **Impact of exclusive enteral**

- nutrition on body composition and circulating micronutrients in plasma and erythrocytes of children with active Crohn's disease. *Inflamm Bowel Dis.* 2012; 18(9): 1672–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Critch J, Day AS, Otley A, *et al.*: Use of Enteral Nutrition for the Control of Intestinal Inflammation in Pediatric Crohn Disease. *J Pediatr Gastroenterol Nutr.* 2012; 54(2): 298–305.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Ruemmele FM, Veres G, Kolho KL, *et al.*: Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. *J Crohns Colitis.* 2014; 8(10): 1179–207.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Afzal NA, Davies S, Paintin M, *et al.*: Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. *Dig Dis Sci.* 2005; 50(8): 1471–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Swaminath A, Feathers A, Ananthakrishnan AN, *et al.*: Systematic review with meta-analysis: Enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. *Aliment Pharmacol Ther.* 2017; 46(7): 645–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Leach ST, Mitchell HM, Eng WR, *et al.*: Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. *Aliment Pharmacol Ther.* 2008; 28(6): 724–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Ashton JJ, Gavin J, Beattie RM: Exclusive enteral nutrition in Crohn's disease: Evidence and practicalities. *Clin Nutr.* 2019; 38(1): 80–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Suskind DL, Wahbeh G, Gregory N, *et al.*: Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. *J Pediatr Gastroenterol Nutr.* 2014; 58(1): 87–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Suskind DL, Wahbeh G, Cohen SA, *et al.*: Patients Perceive Clinical Benefit with the Specific Carbohydrate Diet for Inflammatory Bowel Disease. *Dig Dis Sci.* 2016; 61(11): 3255–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. **F** Braly K, Williamson N, Shaffer ML, *et al.*: Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr.* 2017; 65(5): 533–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
 41. Cohen SA, Gold BD, Oliva S, *et al.*: Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. *J Pediatr Gastroenterol Nutr.* 2014; 59(4): 516–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. **F** Levine A, Wine E, Assa A, *et al.*: Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. *Gastroenterology.* 2019; 157(2): 440–450.e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 43. **F** Svolos V, Hansen R, Nichols B, *et al.*: Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. *Gastroenterology.* 2019; 156(5): 1354–1367.e6.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 44. Sabino J, Lewis JD, Colombel JF, *et al.*: Treating Inflammatory Bowel Disease With Diet: A Taste Test. *Gastroenterology.* 2019; 157(2): 295–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Orendzki BC, Silverstein TD, Persuitt GM, *et al.*: An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. *Nutr J.* 2014; 13: 5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Prince AC, Myers CE, Joyce T, *et al.*: Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2016; 22(5): 1129–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Lim WC, Wang Y, MacDonald JK, *et al.*: Aminosaliculates for induction of remission or response in Crohn's disease. *Cochrane Database Syst Rev.* 2016; 7: CD008870.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Gordon M, Naidoo K, Thomas AG, *et al.*: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. *Cochrane Database Syst Rev.* 2011; (1): CD008414.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Lim WC, Hanauer S: Aminosaliculates for induction of remission or response in Crohn's disease. *Cochrane Database Syst Rev.* 2010; (12): CD008870.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Akobeng AK, Zhang D, Gordon M, *et al.*: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. *Cochrane Database Syst Rev.* 2016; 9: CD003715.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Turner D, Ruemmele FM, Orlanski-Meyer E, *et al.*: Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care- an Evidence-Based Guideline from ECCO and ESPGHAN. *J Pediatr Gastroenterol Nutr.* 2018; 67: 257–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Levine A, Yerushalmi B, Kori M, *et al.*: Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study. *J Crohns Colitis.* 2017; 11(8): 970–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Turner D, Yerushalmi B, Kori M, *et al.*: Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. *J Crohns Colitis.* 2017; 11(5): 527–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Wang Y, Parker CE, Bhanji T, *et al.*: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev.* 2016; 4: CD000543.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Wang Y, Parker CE, Feagan BG, *et al.*: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev.* 2016; (5): CD00054.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Lang A, Salomon N, Wu JC, *et al.*: Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. *Clin Gastroenterol Hepatol.* 2015; 13(8): 1444–9.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Boyle BM, Kappelman MD, Colletti RB, *et al.*: Routine use of thiopurines in maintaining remission in pediatric Crohn's disease. *World J Gastroenterol.* 2014; 20(27): 9185–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Zitomersky NL, Bousvaros A: Medical therapies for Crohn disease in children and adolescents. In: UpToDate. UpToDate, Waltham, MA.
[Reference Source](#)
 59. Hanauer SB: What to take from TREAT? *Am J Gastroenterol.* 2012; 107(9): 1423–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Konidari A, Anagnostopoulos A, Bonnett LJ, *et al.*: Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. *Br J Clin Pharmacol.* 2014; 78(3): 467–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Gearry RB, Barclay ML: Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. *J Gastroenterol Hepatol.* 2005; 20(8): 1149–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Lichtenstein GR: Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. *Gastroenterology.* 2004; 127(5): 1558–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Markowitz J, Grancher K, Kohn N, *et al.*: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. *Gastroenterology.* 2000; 119(4): 895–902.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. *Gastroenterology.* 1998; 115(4): 813–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Israeli E, Goldin E, Fishman S, *et al.*: Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. *Clin Exp Immunol.* 2015; 181(2): 362–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 66. McDonald JW, Tsoulis DJ, MacDonald JK, *et al.*: Methotrexate for induction of remission in refractory Crohn's disease. *Cochrane Database Syst Rev.* 2012; 12: CD003459.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Patel V, Wang Y, MacDonald JK, *et al.*: Methotrexate for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev.* 2014; (8): CD006884.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Chande N, Wang Y, MacDonald JK, *et al.*: Methotrexate for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev.* 2014; (8): CD006618.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 69. **F** Wang Y, MacDonald JK, Vandermeer B, *et al.*: Methotrexate for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev.* 2015; (8): CD007560.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
 70. Herfarth H, Barnes EL, Valentine JF, *et al.*: Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. *Gastroenterology.* 2018; 155(4): 1098–1108.e9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 71. Colman RJ, Lawton RC, Dubinsky MC, *et al.*: Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. *Inflamm Bowel Dis.* 2018; 24(10): 2135–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Feagan BG, Rochon J, Fedorak RN, *et al.*: Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. *N Engl J Med.* 1995; 332(5): 292–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Bianchi G, Caporali R, Todoerti M, *et al.*: Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of

- Administration.** *Adv Ther.* 2016; 33(3): 369–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Valentino PL, Church PC, Shah PS, *et al.*: Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis. *Inflamm Bowel Dis.* 2014; 20(1): 47–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Shea B, Swinden MV, Ghogomu ET, *et al.*: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *J Rheumatol.* 2014; 41(6): 1049–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. Ortiz Z, Shea B, Suarez Almazor M, *et al.*: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *Cochrane Database Syst Rev.* 2000; (2): CD000951.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Hyams J, Crandall W, Kugathasan S, *et al.*: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. *Gastroenterology.* 2007; 132(3): 863–73; quiz 1165–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Singh N, Rosenthal CJ, Melmed GY, *et al.*: Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis.* 2014; 20(10): 1708–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Vande Casteele N, Khanna R, Levesque BG, *et al.*: The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. *Gut.* 2015; 64(10): 1539–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. Hyams JS, Lerer T, Griffiths A, *et al.*: Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. *Inflamm Bowel Dis.* 2009; 15(6): 816–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Hyams J, Damaraju L, Blank M, *et al.*: Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. *Clin Gastroenterol Hepatol.* 2012; 10(4): 391–399.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. Vande Casteele N, Gils A: Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs? *Dig Dis Sci.* 2015; 60(9): 2571–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Levesque BG, Greenberg GR, Zou G, *et al.*: A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. *Aliment Pharmacol Ther.* 2014; 39(10): 1126–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 84. Fasanmade AA, Adedokun OJ, Blank M, *et al.*: Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. *Clin Ther.* 2011; 33(7): 946–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
 85. Frymoyer A, Piester TL, Park KT: Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease. *J Pediatr Gastroenterol Nutr.* 2016; 62(5): 723–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 86. Papamichael K, Vande Casteele N, Ferrante M, *et al.*: Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. *Inflamm Bowel Dis.* 2017; 23(9): 1510–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 87. Adedokun OJ, Xu Z, Padgett L, *et al.*: Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. *Inflamm Bowel Dis.* 2013; 19(13): 2753–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
 88. Hofmekler T, Bertha M, McCracken C, *et al.*: Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr.* 2017; 64(4): 580–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 89. Hyams JS, Griffiths A, Markowitz J, *et al.*: Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. *Gastroenterology.* 2012; 143(2): 365–374.e2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 90. Dubinsky MC, Rosh J, Faubion WA Jr, *et al.*: Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease. *Inflamm Bowel Dis.* 2016; 22(4): 886–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 91. Faubion WA, Dubinsky M, Ruemmele FM, *et al.*: Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. *Inflamm Bowel Dis.* 2017; 23(3): 453–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 92. Dziechciarz P, Horvath A, Kierkuś J: Efficacy and Safety of Adalimumab for Paediatric Crohn's Disease: A Systematic Review. *J Crohns Colitis.* 2016; 10(10): 1237–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 93. Thorlund K, Druyts E, Mills EJ, *et al.*: Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis. *J Crohns Colitis.* 2014; 8(7): 571–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
 94. Volonaki E, Motalib M, Kiparissi F, *et al.*: Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis. *Eur J Gastroenterol Hepatol.* 2015; 27(12): 1425–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 95. Papamichael K, Cheifetz AS, Melmed GY, *et al.*: Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol.* 2019; 17(9): 1655–1668.e3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 96. Feuerstein JD, Nguyen GC, Kupfer SS, *et al.*: American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. *Gastroenterology.* 2017; 153(3): 827–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 97. Hyams JS, Chan D, Adedokun OJ, *et al.*: Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit. *Inflamm Bowel Dis.* 2017; 23(12): 2227–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 98. Pastore S, Naviglio S, Canuto A, *et al.*: Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting. *Paediatr Drugs.* 2018; 20(2): 165–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 99. Hyams JS, Dubinsky MC, Baldassano RN, *et al.*: Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. *Gastroenterology.* 2017; 152(8): 1901–1914.e3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 100. Lemaitre M, Kirchgessner J, Rudnichi A, *et al.*: Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. *JAMA.* 2017; 318(17): 1679–1686.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 101. Eickstaedt JB, Killpack L, Tung J, *et al.*: Psoriasis and Psoriasisiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. *Pediatr Dermatol.* 2017; 34(3): 253–260.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 102. Jacobstein DA, Markowitz JE, Kirschner BS, *et al.*: Premedication and infusion reactions with infliximab: Results from a pediatric inflammatory bowel disease consortium. *Inflamm Bowel Dis.* 2005; 11(5): 442–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 103. Cozijnsen MA, Escher JC, Griffiths A, *et al.*: Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease. *Inflamm Bowel Dis.* 2015; 21(4): 951–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
 104. Colombel JF, Sandborn WJ, Reinisch W, *et al.*: Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med.* 2010; 362(15): 1383–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 105. Colombel JF, Adedokun OJ, Gasink C, *et al.*: Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. *Clin Gastroenterol Hepatol.* 2019; 17(8): 1525–1532.e1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 106. Terdiman JP, Gruss CB, Heidelbaugh JJ, *et al.*: American Gastroenterological Association Institute guideline on the Use of thiopurines, methotrexate, and anti-TNF- α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. *Gastroenterology.* 2013; 145(6): 1459–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
 107. Kierkuś J, Iwańczak B, Wegner A, *et al.*: Monotherapy With Infliximab Versus Combination Therapy in the Maintenance of Clinical Remission in Children With Moderate to Severe Crohn Disease. *J Pediatr Gastroenterol Nutr.* 2015; 60(5): 580–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 108. Hyams JS, Ruemmele F, Colletti RB, *et al.*: Sa1153 Impact of Concomitant Immunosuppressant Use on Adalimumab Efficacy in Children With Moderately to Severely Active Crohn's Disease: Results From IMaGINE 1. *Gastroenterology.* 2014; 146(5): S–214.
[Publisher Full Text](#)
 109. Rosh JR, Lerer T, Markowitz J, *et al.*: Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. *Am J Gastroenterol.* 2009; 104(12): 3042–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 110. Assa A, Hartman C, Weiss B, *et al.*: Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. *J Crohns Colitis.* 2013; 7(5): 369–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 111. Nuti F, Viola F, Civitelli F, *et al.*: Biological therapy in a pediatric Crohn disease population at a referral center. *J Pediatr Gastroenterol Nutr.* 2014; 58(5): 582–7.
[PubMed Abstract](#) | [Publisher Full Text](#)

112. Gouldthorpe O, Catto-Smith AG, Alex G, *et al.*: **Loss of response to long-term infliximab therapy in children with Crohn's disease.** *Pharmaceuticals (Basel)*. 2013; 6(10): 1322–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. Vahabnezhad E, Rabizadeh S, Dubinsky MC: **A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.** *Inflamm Bowel Dis*. 2014; 20(4): 606–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Russell RK, Wilson ML, Loganathan S, *et al.*: **A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease.** *Aliment Pharmacol Ther*. 2011; 33(8): 946–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
115. Church PC, Guan J, Walters TD, *et al.*: **Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.** *Inflamm Bowel Dis*. 2014; 20(7): 1177–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
116. Grossi V, Lerer T, Griffiths A, *et al.*: **Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.** *Clin Gastroenterol Hepatol*. 2015; 13(10): 1748–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
117. Yarur AJ, Jain A, Hauenstein SI, *et al.*: **Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.** *Inflamm Bowel Dis*. 2016; 22(2): 409–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
118. **F** Day AS, Gulati AS, Patel N, *et al.*: **The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.** *J Pediatr Gastroenterol Nutr*. 2018; 66(2): 361–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
119. Beaugier L, Brousse N, Bouvier AM, *et al.*: **Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.** *Lancet*. 2009; 374(9701): 1617–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
120. Kotlyar DS, Blonski W, Diamond RH, *et al.*: **Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality.** *Am J Gastroenterol*. 2010; 105(10): 2299–301.
[PubMed Abstract](#) | [Publisher Full Text](#)
121. Kotlyar DS, Osterman MT, Diamond RH, *et al.*: **A systematic review of factors that contribute to hepatosplenic T-Cell lymphoma in patients with inflammatory bowel disease.** *Clin Gastroenterol Hepatol*. 2011; 9(1): 36–41.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
122. Armuzzi A, Felice C: **Natalizumab in Crohn's disease: past and future areas of applicability.** *Ann Gastroenterol*. 2013; 26(3): 189–190.
[PubMed Abstract](#) | [Free Full Text](#)
123. **F** Chudy-Onwugaje KO, Christian KE, Farraye FA, *et al.*: **A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.** *Inflamm Bowel Dis*. 2019; 25(5): 820–830.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
124. Hyams JS, Wilson DC, Thomas A, *et al.*: **Natalizumab therapy for moderate to severe Crohn disease in adolescents.** *J Pediatr Gastroenterol Nutr*. 2007; 44(2): 185–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
125. Singh N, Deshpande R, Rabizadeh S, *et al.*: **Real World Experience With Natalizumab at a Tertiary Care Pediatric IBD Center.** *J Pediatr Gastroenterol Nutr*. 2016; 62(6): 863–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
126. Mosli MH, MacDonald JK, Bickston SJ, *et al.*: **Vedolizumab for induction and maintenance of remission in ulcerative colitis: A Cochrane systematic review and meta-analysis.** *Inflamm Bowel Dis*. 2015; 21(5): 1151–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
127. **F** Sandborn WJ, Feagan BG, Rutgeerts P, *et al.*: **Vedolizumab as induction and maintenance therapy for Crohn's disease.** *N Engl J Med*. 2013; 369(8): 711–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
128. **F** Feagan BG, Rutgeerts P, Sands BE, *et al.*: **Vedolizumab as induction and maintenance therapy for ulcerative colitis.** *N Engl J Med*. 2013; 369(8): 699–710.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
129. **F** Feagan BG, Rubin DT, Danese S, *et al.*: **Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.** *Clin Gastroenterol Hepatol*. 2017; 15(2): 229–239.e5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
130. **F** Feagan BG, Lasch K, Lissos T, *et al.*: **Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.** *Clin Gastroenterol Hepatol*. 2019; 17(1): 130–138.e7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
131. Conrad MA, Stein RE, Maxwell EC, *et al.*: **Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.** *Inflamm Bowel Dis*. 2016; 22(10): 2425–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
132. **F** Hamel B, Wu M, Hamel EO, *et al.*: **Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis.** *BMJ Open Gastroenterol*. 2018; 5(1): e000195.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
133. **F** Ledder O, Assa A, Levine A, *et al.*: **Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.** *J Crohns Colitis*. 2017; 11(10): 1230–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
134. Singh N, Rabizadeh S, Jossen J, *et al.*: **Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.** *Inflamm Bowel Dis*. 2016; 22(9): 2121–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
135. **F** Schneider AM, Weghuber D, Hetzer B, *et al.*: **Vedolizumab use after failure of TNF- α antagonists in children and adolescents with inflammatory bowel disease.** *BMC Gastroenterol*. 2018; 18(1): 140.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
136. **F** Plevris N, Chuah CS, Allen RM, *et al.*: **Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.** *J Crohns Colitis*. 2019; 13(9): 1111–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
137. Dulai PS, Singh S, Jiang X, *et al.*: **The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.** *Am J Gastroenterol*. 2016; 111(8): 1147–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
138. Vermeire S, O'Byrne S, Keir M, *et al.*: **Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.** *Lancet*. 2014; 384(9940): 309–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
139. **F** Feagan BG, Sandborn WJ, Gasink C, *et al.*: **Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.** *N Engl J Med*. 2016; 375(20): 1946–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
140. **F** Rutgeerts P, Gasink C, Chan D, *et al.*: **Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.** *Gastroenterology*. 2018; 155(4): 1045–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
141. Rinawi F, Rosenbach Y, Assa A, *et al.*: **Ustekinumab for Resistant Pediatric Crohn Disease.** *J Pediatr Gastroenterol Nutr*. 2016; 62(4): e34–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
142. Bishop C, Simon H, Suskind D, *et al.*: **Ustekinumab in Pediatric Crohn Disease Patients.** *J Pediatr Gastroenterol Nutr*. 2016; 63(3): 348–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
143. Dayan JR, Dolinger M, Benkov K, *et al.*: **Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.** *J Pediatr Gastroenterol Nutr*. 2019; 69(1): 61–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
144. Coskun M, Salem M, Pedersen J, *et al.*: **Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.** *Pharmacol Res*. 2013; 76: 1–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
145. Friedman S: **Tofacitinib for Ulcerative Colitis - A Promising Step Forward.** *N Engl J Med*. 2017; 376(18): 1792–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
146. **F** Flamant M, Rigail J, Paul S, *et al.*: **Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.** *Drugs*. 2017; 77(10): 1057–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
147. **F** Sandborn WJ, Su C, Sands BE, *et al.*: **Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.** *N Engl J Med*. 2017; 376(18): 1723–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
148. **F** Hanauer S, Panaccione R, Danese S, *et al.*: **Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.** *Clin Gastroenterol Hepatol*. 2019; 17(1): 139–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
149. **F** Vermeire S, Schreiber S, Petryka R, *et al.*: **Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.** *Lancet*. 2017; 389(10066): 266–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Athos Bousvaros**

Department of Medicine, Boston Children's Hospital, Boston, MA, USA

Naamah Zitomersky

Department of Medicine, Boston Children's Hospital, Boston, MA, USA

Competing Interests: No competing interests were disclosed.

2. **Jaroslaw Kierkus**

Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children's Memorial Health Institute, Warsaw, Poland

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research